Genetic polymorphism related to monocyte-macrophage function is associated with graft-versus-host disease by Hyvarinen, Kati et al.
1SCIenTIFIC RePoRTS | 7: 15666  | DOI:10.1038/s41598-017-15915-3
www.nature.com/scientificreports
Genetic polymorphism related to 
monocyte-macrophage function is 
associated with graft-versus-host 
disease
Kati Hyvärinen  1, Jarmo Ritari1, Satu Koskela1, Riitta Niittyvuopio2, Anne Nihtinen2,  
Liisa Volin2, David Gallardo3 & Jukka Partanen  1
Despite detailed human leukocyte antigen (HLA) matching and modern immunosuppressive therapy, 
severe graft-versus-host disease (GvHD) remains a major hurdle for successful allogeneic hematopoietic 
stem cell transplantation (HSCT). As the genetic diversity in GvHD complicates the systematic 
discovery of associated variants across populations, we studied 122 GvHD-associated single nucleotide 
polymorphisms (SNPs) in 492 HLA-matched sibling HSCT donor-recipient pairs from Finland and 
Spain. The association between these candidate SNPs and grade III–IV acute GvHD and extensive 
chronic GvHD was assessed. The functional effects of the variants were determined using expression 
and cytokine quantitative trait loci (QTL) database analyses. Clear heterogeneity was observed in the 
associated markers between the two populations. Interestingly, the majority of markers, such as those 
annotated to IL1, IL23R, TLR9, TNF, and NOD2 genes, are related to the immunological response 
by monocytes-macrophages to microbes, a step that precedes GvHD as a result of intestinal lesions. 
Furthermore, cytokine QTL analysis showed that the GvHD-associated markers regulate IL1β, IFNγ, 
and IL6 responses. These results support a crucial role for the anti-microbial response in GvHD risk. 
Furthermore, despite apparent heterogeneity in the genetic markers associated with GvHD, it was 
possible to identify a biological pathway shared by most markers in both populations.
Allogeneic hematopoietic stem cell transplantation (HSCT) is a well-established curative treatment for many 
hematological malignancies. Graft-versus-host disease (GvHD) is the major life-threatening complication of 
HSCT. GvHD is mediated by donor immune cells in the graft, which recognize the patient’s tissues as foreign and 
destroy them. As the recipient is immunocompromised due to conditioning and immunosuppressive medication, 
the immune system of the recipient is not able to kill the foreign cells of the graft. GvHD occurs in 20–50% of 
HSCTs1.
One critical step in GvHD initiation is extensive immune activation due to microbial antigens that leak from 
the gastrointestinal track due to conditioning. The microbial antigens are detected by antigen-presenting cells 
(APCs) via pathogen-associated molecular pattern (PAMP) receptors, such as Toll-like receptors (TLRs) and 
NODs, leading to the activation of these cells. The activation of APCs leads to a cytokine storm, i.e., the pro-
duction of high levels of cytokines, such as interleukin (IL)6, interferon (IFN)γ, IL23 and tumor necrosis factor 
(TNF) which, in turn, activate other immune cells1–3.
The outcome of HSCT is strongly influenced by the genetic differences between recipient/donor pairs4. The 
golden rule is genetic similarity or identity in the human leukocyte antigen (HLA) genes located in the major his-
tocompatibility complex (MHC) on chromosome 6. However, there is evidence that HLA identity is not sufficient 
to prevent GvHD. Minor histocompatibility antigens5, mismatches in gene deletions6, non-HLA polymorphisms 
in immunoregulatory molecules7–12, drug-metabolizing genes13,14, and regulatory elements e.g., non-coding 
RNAs11, affect the risk of adverse outcomes15. In fact, we can assume GvHD as a multifactorial trait with a genetic 
component, in which the HLA matching is a crucial but not sufficient factor. As noted by Warren et al.4, while 
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clinical HLA testing – sequencing of certain HLA gene exons - certainly focuses on functionally relevant varia-
tions, it encompasses only 1/1000th of the entire MHC sequence, or 1000000th part of the whole genome.
Genome-wide association (GWA) studies provide a systematic view of the genetic architecture and genetic 
risk markers of GvHD. One challenge for GWA studies in HSCT is diagnostic and treatment heterogeneity and 
the fact that the outcome may depend on properties of both the donor and recipient. It has been estimated that at 
least a few thousand HSCTs should be studied to reach sufficient statistical power for a GWA study4,15. To begin 
to tackle this challenge, we used an alternative approach described by Chien et al.10 and screened previously 
reported genetic associations in two additional populations with the rationale that, if replicated independently in 
many populations, the association may be genuine. We evaluated the previously reported GvHD-associated single 
nucleotide polymorphisms (SNPs) in two HLA-matched sibling allogeneic HSCT cohorts derived from Finnish 
and Spanish populations. To obtain coherent genetic information, the Immunochip array data were imputed and 
strictly filtered. We further analyzed the downstream functional effects of the associated SNPs to identify the 
disease-related biological pathways involved.
Results
Selection of the candidate SNPs. The 40 SNPs discovered by Chien et al.10 were included in the present 
analysis. The PubMed literature search from April 30, 2011 to January 31, 2017 identified 26 studies reporting 
an additional 82 SNPs associated with GvHD. From these 122 SNPs, 50 and 64 were found in the imputed and 
filtered Finnish and Spanish genotype datasets, respectively. The complete list of analyzed SNPs is presented in 
Supplementary Tables 1 and 2, and detailed data of imputed and genotyped SNPs associated with GvHD in the 
current study are depicted in Supplementary Tables 2 and 3. All Hardy–Weinberg equilibrium (HWE) P-values 
were >6 × 10−4 and no call rate was less than 93%. Metrics depicting the success of imputation were close to 1, 
implicating that these SNPs were imputed with high certainty.
Candidate SNPs associated with acute and chronic GvHD in the Finnish cohort. In the 
Finnish cohort, we evaluated the association between 50 candidate SNPs and both acute GvHD (aGvHD) and 
chronic GvHD (cGvHD) outcomes. A summary of these associations at an α-level <0.05 is presented in Table 1.
Two recipient and four donor genotypes displayed an association with aGvHD. These results demonstrate an 
association between recipient rs2523957 (MICD) and rs7294 (PRSS53/VKRC1) and an increased risk of aGvHD 
(P = 0.001 and 0.010, respectively). Among the donors, SNPs rs3917225 (IL1R1, P = 0.022), rs2523957 (MICD, 
P < 0.001), rs1800629 (TNF, P = 0.029), and rs2233409 (NFKBIA, P = 0.031) predisposed recipients to an adverse 
outcome. It is important to note that the minor allele G at rs2523957 (pseudogene MICD) was associated with 
an increased risk of aGvHD in both the recipient (odds ratio [OR] 2.82, 95% confidence interval [CI]: 1.51–5.27, 
P = 0.001) and donor (OR 2.75, 95% CI: 1.55–4.87, P < 0.001) genotypes.
Two recipient and two donor genotypes showed associations with cGvHD. Recipient genotypes at rs16944 
(IL1b) and rs6500328 (NOD2) resulted in a borderline increased risk of cGvHD (P = 0.047 and 0.035, respec-
tively). The donor missense genotype at rs2075800 (HSPA1L) displayed a borderline protective association with 
cGvHD (OR 0.62, 95% CI: 0.38–0.99, P = 0.046). A synonymous codon at rs1137282 (KRAS) reduced the risk of 
cGvHD (OR 0.46, 95% CI: 0.24–0.88, P = 0.017).
Candidate SNPs associated with acute and chronic GvHD in the Spanish cohort. A summary 
of the associations identified between candidate SNPs and aGvHD and cGvHD in the Spanish cohort is pre-
sented in Table 2. In total, 64 SNPs were evaluated. Table 2 shows the associations with an α-level <0.05. In the 
Spanish cohort, four recipient and six donor genotypes were associated with aGvHD. In both the recipient and 
donor genotypes, the minor allele A at rs2800230 (not in the gene) was associated with protection from aGvHD 
Outcome Recipient/Donor Gene* SNP† CHR A1 A2
Odds ratio (95% 
confidence interval)‡ P‡
aGvHD Recipient MICD rs2523957 6 G A 2.82 (1.51–5.27) 0.001
aGvHD Recipient PRSS53/VKRC1 rs7294 16 T C 2.26 (1.21–4.25) 0.010
aGvHD Donor IL1R1 rs3917225 2 A G 1.92 (1.09–3.37) 0.022
aGvHD Donor MICD rs2523957 6 G A 2.75 (1.55–4.87) <0.001
aGvHD Donor TNF rs1800629 6 A G 2.24 (1.07–4.70) 0.029
aGvHD Donor NFKBIA rs2233409 14 A G 1.97 (1.05–3.70) 0.031
cGvHD Recipient IL1B rs16944 2 A G 1.55 (1.00–2.38) 0.047
cGvHD Recipient NOD2 rs6500328 16 G A 1.58 (1.03–2.41) 0.035
cGvHD Donor HSPA1L rs2075800 6 T C 0.62 (0.38–0.99) 0.046
cGvHD Donor KRAS rs1137282 12 G A 0.46 (0.24–0.88) 0.017
Table 1. Candidate SNPs associated with acute and chronic GvHD in the Finnish cohort. SNP indicates 
single nucleotide polymorphism; CHR, chromosome; A1, minor allele; A2, major allele; aGvHD, acute graft-
versus-host disease grade III–IV; and cGvHD, extensive chronic graft-versus-host disease. *Annotation of 
SNP according to National Center for Biotechnology Information dbSNP database. †Only SNPs showing an 
association at an α-level <0.05 are presented. ‡Odds ratios and P-values have been determined with PLINK 1.07 
standard case/control association analysis, 1df chi-square allelic test.
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(recipient OR 0.57, 95% CI: 0.34–0.95, P = 0.031; donor OR 0.58, 95% CI: 0.35–0.95, P = 0.029). The IL1B SNP 
rs1143634 (P = 0.012) and the IL1A-annotated SNP rs1800587 (P = 0.031) conferred susceptibility to aGvHD in 
the recipient genotype. The minor allele G at rs2862833 (Fas cell surface death receptor, FAS) was associated with 
protection from aGvHD (OR 0.52, 95% CI: 0.31–0.87, P = 0.013).
In Spanish donors, IL10 promoter SNPs rs1800872 and rs1800871 increased the risk of aGvHD (OR 2.19, 95% 
CI: 1.33–3.63, P = 0.002 for both SNPs). The IL10RB missense variation at rs11209026 was also associated with 
an increased risk of aGvHD (OR 1.96, 95% CI: 1.17–3.28, P = 0.010). However, the IL10 promoter SNP rs1800896 
displayed a protective minor allele C association with the disease (OR 0.48, 95% CI: 0.29–0.80, P = 0.004).
Two donor genotype TLR9 SNPs (rs352140, P = 0.018 and rs352139, P = 0.023) were associated with protec-
tion from cGvHD. An adverse association with cGvHD was found in cases with the recipient genotype IL23R 
missense SNP rs11209026 (OR 2.61, 95% CI: 1.13–6.04, P = 0.020).
Expression quantitative trait loci analysis of candidate SNPs. The downstream effects of 
GvHD-associated SNPs on mRNA expression were determined using the Blood expression quantitative trait 
loci (eQTL) Database generated by Westra et al.16. When analyzing all 21 SNPs showing an association with 
aGvHD or cGvHD in the current study, several SNPs were determined to affect the expression of nearby genes 
(Tables 3 and 4). No significant trans-eQTL effects were detected.
In the Finnish cohort (Table 3), SNP rs2075800, located within the heat shock protein A1-like (HSPA1L) 
gene, protected individuals from cGvHD and was associated with increased expression of HSPA and the adja-
cent HSPA1B gene, with an FDR level <0.05 (HSPA1B Z-score 20.06, P = 1.78 × 10−89; HSPA1L Z-score 8.17, 
P = 3.02 × 10−16). In both the recipient and donor genotypes, aGvHD-predisposing rs2523957 (pseudogene 
MICD) was associated with reduced expression of HLA-G, with a Z-score = −13.89 and a P = 7.18 × 10−44, 
and increased expression of HLA-F, with a Z-score = 15.64 and a P = 3.65 × 10−55. Additionally, the cis-eQTL 
results for TNF revealed that the disease-predisposing SNP rs1800629 reduced expression of the TNF gene 
(P = 1.28 × 10−7). It is also important to note that the HSPA1L, HSPA1B, MICD, and TNF genes are all located 
in the MHC region. The intronic NOD2 rs6500328 decreased expression of the NOD2 gene (Z-score −22.76, 
P = 1.10 × 10−114) and the minor allele G was identified as a risk factor in the outcome association analysis 
(Table 1).
In the Spanish cohort, two TLR9-annotated SNPs were associated with GvHD (Table  4). The 
aGvHD-protective SNPs, rs352140 and rs352139, increased the expression of PPM1M (rs352140 Z-score 17.02, 
P = 5.90 × 10−65; rs352139 Z-score 17.2, P = 2.71 × 10−66). The protective SNP rs2862833, a downstream variant 
of the FAS gene, increased the expression of FAS (Z-score 10.8, P = 3.51 × 10−27) and the STAMBPL1/ACTA2 
locus (Z-score 38.25, P = 9.81 × 10−198). IL10 promoter SNPs, rs1800872, rs1800871, and rs1800896, did not 
demonstrate any significant cis-eQTL association. The aGvHD-predisposing IL10RB missense SNP rs2834167 
was associated with increased expression of IL10RB, with a Z-score = 7.01 and a P = 2.44 × 10−12.
Cytokine QTL associations of candidate SNPs. The cytokine storm plays an important role in the ini-
tiation phase of GvHD. Therefore, we examined cytokine QTL effects of the associated SNPs by utilizing the 
cytokine QTL database recently published by Li Y et al.17. The results are presented in Tables 5 and 6.
In the Finnish cohort, six of seven SNPs associated with an increased risk of GvHD were linked with alter-
ations in the production of IL6 and IFNγ by peripheral blood mononuclear cells (PBMCs) at an alpha level 
<0.05 (Table 5). When examining the link between predisposing genotypes at MICD and PRSS53/VKRC1 loci 
Outcome Recipient/Donor Gene* SNP† CHR A1 A2
Odds ratio‡ (95% 
confidence interval) P‡
aGvHD Recipient Not in gene rs2800230 1 A G 0.57 (0.34–0.95) 0.031
aGvHD Recipient IL1A rs1800587 2 A G 1.75 (1.05–2.92) 0.031
aGvHD Recipient IL1B rs1143634 2 A G 2.00 (1.16–3.45) 0.012
aGvHD Recipient FAS rs2862833 10 G A 0.52 (0.31–0.87) 0.013
aGvHD Donor IL10 rs1800872 1 T G 2.19 (1.33–3.63) 0.002
aGvHD Donor IL10 rs1800871 1 A G 2.19 (1.33–3.63) 0.002
aGvHD Donor IL10 rs1800896 1 C T 0.48 (0.29–0.80) 0.004
aGvHD Donor IL10RB rs2834167 21 G A 1.96 (1.17–3.28) 0.010
aGvHD Donor Not in gene rs2800230 1 A G 0.58 (0.35–0.95) 0.029
aGvHD Donor LOC105373109 rs10737416 1 A C 1.73 (1.05–2.85) 0.030
cGvHD Recipient IL23R rs11209026 1 A G 2.61 (1.13–6.04) 0.020
cGvHD Donor TLR9 rs352140 3 C T 0.58 (0.37–0.91) 0.018
cGvHD Donor TLR9 rs352139 3 T C 0.59 (0.38–0.93) 0.023
Table 2. Candidate SNPs associated with acute and chronic GvHD in the Spanish cohort. SNP indicates 
single nucleotide polymorphism; CHR, chromosome; A1, minor allele; A2, major allele; aGvHD, acute graft-
versus-host disease grade III–IV; and cGvHD, extensive chronic graft-versus-host disease. *Annotation of 
SNP according to National Center for Biotechnology Information dbSNP database. †Only SNPs showing an 
association at an α-level <0.05 are presented. ‡Odds ratios and P-values have been determined with PLINK 1.07 
standard case/control association analysis, 1df chi-square allelic test.
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and IL6, the initial stimuli were revealed as fungi Cryptococcus and Candida albicans. Changes in the produc-
tion of IFNγ emerged following stimulation with Bacteroides, Cryptococcus, Stafylococcus aureus, and C. albi-
cans combined with carrying a risk allele at IL1R1, TNF, IL1β, or NOD2, respectively. Donor genotype T at 
the HSPA1L-annotated SNP rs2075800 was combined with whole blood stimulus by phytohaemagglutinin and 
production of IFNγ (P = 0.007).
In the Spanish cohort, the majority of cytokine QTL associations focused on the IL1β and IFNγ responses of 
stimulated PBMCs (Table 6). Recipient SNPs at IL1α and IL1β aGvHD risk loci were significantly associated with 
altered production of IFNγ by PBMCs following stimulation with C. albicans (rs1800587 and rs1071676, P < 0.05 
for both) or Cryptococcus (rs1143634, P = 0.030). Donor aGvHD-predisposing IL10 promoter region genotypes 
at rs1800872 and rs1800871 combined with the IL1β response of Escherichia coli-stimulated PBMCs (P = 0.001). 
However, the aGvHD-protective IL10 SNP, rs1800896, displayed a borderline association with the IFNγ response 
after stimulation with Borrelia burgdorferi (P = 0.049). Donor minor allele G at rs2834167 (IL10RB), having an 
adverse association with aGvHD, combined with altered production of IFNγ by C. albicans-stimulated PBMCs. 
The IL6 response was altered when C. burnetii-stimulated PBMCs were combined with the aGvHD-protective 
genotype at the FAS locus rs2862833 (P = 0.008).
Discussion
To systematically identify genetic loci that are associated with GvHD, we screened previously reported SNPs for 
their genetic associations with aGvHD and cGvHD in a total of 492 HLA-matched sibling HSCT recipient-donor 
pairs. The cohorts were derived from two populations: Finnish and Spanish. The major finding of the present 
study was that, despite clear heterogeneity in GvHD-associated polymorphisms between the two populations, 
the markers share a common feature: they are predominantly annotated with genes that are important in the host 
response to microbial antigens. Furthermore, the functional effects of these polymorphisms were related to the 
same pathways.
The GvHD-associated genes included IL1, IL10, IL23R, TLR9, TNF, and NOD2, which all play a role in 
the host response to microbes. However, it was of further interest that the polymorphisms were determined 
Outcome Recipient/Donor Gene* SNP CHR A1
Risk/
protective† cis-eQTL gene‡ Z-score‡ P‡ FDR‡
aGvHD Recipient + donor MICD rs2523957 6 G Risk HLA-F 15.64 3.65 × 10–55 <0.01
HLA-G −13.89 7.18 × 10−44 <0.01
PPP1R11 −9.09 1.03 × 10−19 <0.01
ZNRD1 5.44 5.27 × 10−8 <0.01
aGvHD Recipient PRSS53/VKRC1 rs7294 16 T Risk STX4 16.17 8.85 × 10−59 <0.01
BCKDK −11.27 1.82 × 10−29 <0.01
ZNF668 −10.78 4.12 × 10−27 <0.01
AC093520.4, ITGAM −6.26 3.73 × 10−10 <0.01
AC135050.5 −5.95 2.68 × 10−9 <0.01
MYST1 5.58 2.38 × 10−8 <0.01
aGvHD Donor IL1R1 rs3917225 2 A Risk IL1R2 3.36 7.73 × 10−4 0.20
aGvHD Donor TNF rs1800629 6 A Risk TNF −5.28 1.28 × 10−7 <0.01
CSNK2B 5.17 2.29 × 10−7 <0.01
LTA −3.21 1.31 × 10−3 0.29
aGvHD Donor NFKBIA rs2233409 14 A Risk — — — —
cGvHD Recipient IL1B rs16944 2 A Risk NT5DC4 3.2 1.36 × 10−3 0.30
cGvHD Recipient NOD2 rs6500328 16 G Risk NOD2 −22.76 1.10 × 10−114 <0.01
cGvHD Donor HSPA1L rs2075800 6 T Protective CSNK2B −22.03 1.47 × 10−107 <0.01
HSPA1B 20.06 1.78 × 10−89 <0.01
HSPA1L 8.17 3.02 × 10−16 <0.01
LY6G5C 5.64 1.75 × 10−8 <0.01
RDBP 5.62 1.90 × 10−8 <0.01
AIF1 5.35 8.77 × 10−8 <0.01
BAT3 4.52 6.13 × 10−6 <0.01
cGvHD Donor KRAS rs1137282 12 G Protective — — — —
Table 3. eQTL analysis of candidate SNPs in the Finnish cohort. SNP indicates single nucleotide 
polymorphism; CHR, chromosome; A1, minor allele; eQTL indicates expressive quantitative trait loci; 
FDR, false detection rate; aGvHD, acute graft-versus-host disease grade III–IV; −, no cis-eQTL records 
found; and cGvHD, extensive chronic graft-versus-host disease. *Annotation of SNP according to National 
Center for Biotechnology Information dbSNP database. †Risk/protective outcome status of the SNP has been 
determined from the association results (Table 1). ‡Westra et al.16. Blood eQTL Browser http://genenetwork.nl/
bloodeqtlbrowser/.
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to regulate the expression levels of cytokines IL1β, IL6, and IFNγ, all of which are important mediators of the 
cytokine storm.
Several SNPs annotated to pathogen recognition receptors (PRRs) have been previously associated with 
GvHD7,8. In TLR9, which detects intracellular bacterial single-stranded CpG-DNA, we found protective poly-
morphisms that showed no direct effect on expression of the TLR9 gene in two of the QTL databases utilized 
herein. The intronic risk SNP rs6500328 in the NOD2 gene was associated with reduced expression of the NOD2 
gene and was also associated with IFNγ expression in the cytokine QTL database. The cytokine QTL analysis 
demonstrated complex crosstalk between the associated SNPs, their direct QTL effects and the response of par-
ticular cell populations to microbial antigens. To further support a role for PRRs in GvHD, our unpublished 
Outcome Recipient/Donor Gene* SNP CHR A1
Risk/
protective† cis-eQTL gene‡ Z-score‡ P‡ FDR‡
aGvHD Recipient + donor Not in gene rs2800230 1 A Protective — — — —
aGvHD Recipient IL1A rs1800587 2 A Risk SLC20A1 −4.03 5.62 × 10−5 0.02
CHCHD5 −3.59 3.31 × 10−4 0.11
aGvHD Recipient IL1B rs1143634 2 A Risk CHCHD5 −4.1 4.10 × 10−5 0.02
SLC20A1 −3.19 1.43 × 10−3 0.31
aGvHD Recipient FAS rs2862833 10 G Protective STAMBPL1, ACTA2 38.25 9.81 × 10−198 <0.01
FAS 10.8 3.51 × 10−27 <0.01
aGvHD Donor IL10 rs1800872 1 T Risk — — — —
aGvHD Donor IL10 rs1800871 1 A Risk — — — —
aGvHD Donor IL10 rs1800896 1 C Protective RASSF5 −3.51 4.56 × 10−4 0.14
aGvHD Donor LOC105373109 rs10737416 1 A Risk — — — —
aGvHD Donor IL10RB rs2834167 21 G Risk IL10RB 7.01 2.44 × 10−12 <0.01
IFNAR1 6.14 8.10 × 10−10 <0.01
cGvHD Recipient IL23R rs11209026 1 A Risk — — — —
cGvHD Donor TLR9 rs352140 3 C Protective PPM1M 17.02 5.90 × 10−65 <0.01
DNAH1 4.59 4.51 × 10−6 <0.01
cGvHD Donor TLR9 rs352139 3 T Protective PPM1M 17.2 2.71 × 10−66 <0.01
DNAH1 7.31 2.69 × 10−13 <0.01
Table 4. eQTL analysis of candidate SNPs in the Spanish cohort. SNP indicates single nucleotide 
polymorphism; CHR, chromosome; A1, minor allele; eQTL indicates expressive quantitative trait loci; 
FDR, false detection rate; aGvHD, acute graft-versus-host disease grade III–IV; –, no cis-eQTL records 
found; and cGvHD, extensive chronic graft-versus-host disease. *Annotation of SNP according to National 
Center for Biotechnology Information dbSNP database. †Risk/protective outcome status of the SNP has been 
determined from the association results (Table 2). ‡Westra et al.16. Blood eQTL Browser http://genenetwork.nl/
bloodeqtlbrowser/.
Outcome Recipient/Donor Gene* SNP CHR A1
Risk/
protective† Stimulus‡
Cell 
system‡
Stimulation 
days‡ Cytokine‡ P‡
aGvHD Recipient +donor MICD rs2523957 6 G Risk Cryptococcus PBMC 1 IL6 0.009
aGvHD Recipient PRSS53/VKRC1 rs7294 16 T Risk C. albicans conidia PBMC 1 IL6 0.015
aGvHD Donor IL1R1 rs3917225 2 A Risk Bacteroides PBMC 7 INFy 0.014
aGvHD Donor TNF rs1800629 6 A Risk Cryptococcus PBMC 7 INFy 0.016
aGvHD Donor NFKBIA rs2233409 14 A Risk — — — — —
cGvHD Recipient IL1B rs16944 2 A Risk S. aureus PBMC 7 INFy 0.003
cGvHD Recipient NOD2 rs6500328 16 G Risk C. albicans hyphae PBMC 7 INFy 0.031
cGvHD Donor HSPA1L rs2075800 6 T Protective PHA WB 2 INFy 0.007
cGvHD Donor KRAS rs1137282 12 G Protective — — — — —
Table 5. Cytokine QTL associations of candidate SNPs in the Finnish cohort. SNP indicates single nucleotide 
polymorphism; CHR, chromosome; A1, minor allele; aGvHD, acute graft-versus-host disease grade III–IV; 
PBMC, peripheral blood mononuclear cell; − no cytokine quantitative trait loci records found; cGvHD, 
extensive chronic graft-versus-host disease; PHA, phytohaemagglutinin; and WB, whole blood. *Annotation of 
SNP according to National Center for Biotechnology Information dbSNP database. †Risk/protective outcome 
status of the SNP has been determined from the association results (Table 1). ‡The cytokine QTL database 
(https://hfgp.bbmri.nl/), published by Li Y et al.17.
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studies suggest that LPS-recognizing TLR4 displays intronic minor alleles at rs12377632 and rs1927907, both 
of which were associated with GvHD protection and a strong increase in TLR4 expression. The protective TLR4 
genotype at rs1927907 was associated with the IL1β response of C. burnetii-stimulated PBMCs. However, their 
associations with aGvDH have not yet been reported; therefore, these SNPs were not included in the current study 
and should be further analyzed in other populations.
The use of eQTL and cytokine QTL databases allows for demonstration of the functional or downstream 
effects of disease-associated polymorphisms. The eQTL analyses performed herein revealed interesting findings 
and indicated shared pathways. The association between IL10 polymorphisms and GvHD has been established in 
many populations18–21 and it has been assumed to be related to different expression levels of IL10. However, the 
IL10 markers rs1800872 and rs1800871 determined to be associated in the present study showed no eQTL effects 
on IL10 expression, but rather the polymorphisms regulated the IFNγ and IL1β levels produced by PBMCs after 
stimulation with E. coli or B. burgdorferi. In contrast, missense polymorphisms in IL10RB did regulate the level of 
IL10RB and IFNγ in the cytokine eQTL. Hence, each polymorphism may exert various effects at different steps of 
the immune response. Unfortunately, the cytokine database in its present form shows no relationship between the 
allele and the direction of the measured cytokine response, making it difficult to interpret the mechanisms of risk 
alleles. In this regard, GvHD-specific QTL databases would facilitate the functional interpretation of significant 
variants.
A number of SNPs showing an association with GvHD risk in the Finnish cohort mapped to MHC on chro-
mosome 6p21.3. TNF, MICD, and HSPA1L are located relatively close to each other; therefore, the observed asso-
ciations may be derived from a single genetic polymorphism in linkage disequilibrium with the markers analyzed 
here. Alternatively, there may be multiple polymorphisms within the MHC segment associated with the disease. 
For example, emerging evidence indicates multiple novel MHC-associated risk markers for GvHD4,22. Based on 
the present results, it is not possible to pinpoint which marker is the primary or closest to the true risk polymor-
phism. In fact, as long as we do not know the causal SNP, these results only indicate that the genes annotated to 
SNP may influence the risk for GvHD. Differences in linkage disequilibrium between causal and studied SNPs 
result in discrepancies observed between results from different populations as seen also in the present study when 
compared to original findings.
In addition to ethnicity and the genotyping array performed, the two cohorts investigated in this study also 
differed from each other with respect to their clinical HSCT setting. The Finnish cohort was from a single center, 
whereas the Spanish cohort originated from a number of clinics. The stem cell source, conditioning regimen, 
and GvHD prevention procedures varied significantly and may have contributed to the heterogeneity of the 
GvHD-associated SNPs. Combining these typical aspects with well-established GvHD risk factors2,3, such as 
donor and recipient age, transplant gender direction, diagnosis and staging, and infections, may also partially 
explain why, despite numerous GvHD candidate genes and markers studied in recent years, the consistency of 
results across studies has been sparse.
To date, genome-wide studies in GvHD have been reported only among mostly Caucasian23 and Japanese24 
populations. These studies have not reported overlapping or shared risk loci, indicating the heterogeneous nature 
of GvHD genetics. It will be of interest to test whether the utilization of eQTL or pathway approaches similar 
to those used in the present study would reveal common mechanisms behind apparently heterogeneous asso-
ciations. While GWA studies investigating millions of variants require vigorous control of multiple tests, due 
to the replicative nature of the present study, an alpha value <0.05 was selected as the threshold for statistical 
Outcome Recipient/Donor Gene* SNP CHR A1
Risk/
protective† Stimulus‡
Cell 
system‡
Stimulation 
days‡ Cytokine‡ P‡
aGvHD Recipient + donor Not in gene rs2800230 1 A Protective Borreliamix PBMC 7 INFy 0.045
aGvHD Recipient IL1A rs1800587 2 A Risk C. albicans conidia PBMC 7 INFy 0.003
aGvHD Recipient IL1B rs1143634 2 A Risk Cryptococcus PBMC 7 INFy 0.030
aGvHD Recipient FAS rs2862833 10 G Protective C. burnetii Nine mile serum PBMC 1 IL6 0.008
aGvHD Donor IL10 rs1800872 1 T Risk E. Coli PBMC 1 IL1b 0.001
aGvHD Donor IL10 rs1800871 1 A Risk E. Coli PBMC 1 IL1b 0.001
aGvHD Donor IL10 rs1800896 1 C Protective B. burgdorferi PBMC 7 INFy 0.049
aGvHD Donor IL10RB rs2834167 21 G Risk C. albicans hyphae PBMC 7 INFy 0.034
aGvHD Donor LOC105373109 rs10737416 1 A Risk Borreliamix PBMC 7 IL22 0.043
cGvHD Recipient IL23R rs11209026 1 A Risk — — — — —
cGvHD Donor TLR9 rs352140 3 C Protective — — — — —
cGvHD Donor TLR9 rs352139 3 T Protective — — — — —
Table 6. Cytokine QTL associations of candidate SNPs in the Spanish cohort. SNP indicates single nucleotide 
polymorphism; CHR, chromosome; A1, minor allele; aGvHD, acute graft-versus-host disease grade III–IV; 
PBMC, peripheral blood mononuclear cell; −, no cytokine quantitative trait loci records found; and cGvHD, 
extensive chronic graft-versus-host disease. *Annotation of SNP according to National Center for Biotechnology 
Information dbSNP database. †Risk/protective outcome status of the SNP has been determined from the 
association results (Table 2). ‡The cytokine QTL database (https://hfgp.bbmri.nl/), published by Li Y et al.17.
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significance for allele frequency association with GvHD. The fact that the associated genes were functionally 
relevant to GvHD can be regarded as additional supportive evidence.
As demonstrated by the present study and many other association studies8–10,25, individuals may carry genetic 
factors rendering them more susceptible to react immunologically against foreign structures, such as allogeneic 
cells or intestinal microbes. Such a high responder genotype may be helpful in clearing infections but may also 
increase the risk of GvHD. This may be one of the important genetic factors for GvHD risk. We can also assume 
that an increased risk of GvHD results from insufficient histocompatibility; despite good HLA matching, mis-
matches in minor histocompatibility antigens may also play a role in GvHD risk5,6. Another possibility is the 
pharmacogenomic differences in the response to or efficiency of the immunosuppressive treatment13. This has 
been scarcely explored but certainly merits further investigation. Hence, we constructed at least three overlapping 
models for GvHD genetics that most likely act together.
The present study provides further evidence that genetic variation regulating the level of the immune response 
against bacterial antigens is an important non-HLA factor in GvHD susceptibility. Although individual associ-
ated polymorphisms are not necessarily the same throughout different populations, they consistently belong to 
the same regulatory pathways participating in cytokine-mediated inflammation of the intestinal epithelium. It 
is likely that a similar type of heterogeneity can be found in other populations or cohorts, and it remains to be 
determined whether associated markers also belong to the same biological pathway. This heterogeneity implies 
that large genome screens may be needed for clinical GvHD predictions, rather than focusing on only a small 
number of selected genetic markers.
Methods
Literature search. Chien et al.10 identified 41 publications reporting 40 SNPs associated with aGvHD up to 
April 30, 2011, which were included in our analysis. We also performed a PubMed search using the term “acute 
GvHD AND polymorphism” to identify published studies reporting an association analysis of genetic variants 
with GvHD from April 30, 2011 until January 31, 2017. Studies reporting associations at an α-level >0.05 were 
excluded and, from all of the variant types, only SNPs were selected for further analysis.
Study populations. The SNP association analyses were replicated within two separate populations. The 
characteristics of all recipients in these cohorts are presented in Table 7. The Finnish cohort consisted of 301 
HLA-matched recipient/donor sibling pairs having clinical data and DNA samples sent for genotyping. The 
cohort also included 11 individual recipients and 8 donors without the respective sibling. All recipients under-
went allogeneic HSCT at Helsinki University Hospital, Comprehensive Cancer Center, Stem Cell Transplantation 
Unit, Finland, between 1993 and 2006. The pairs were matched to low-resolution level at HLA-A, -B, and -DRB1 
loci. HLA typing was performed with Lymphotype HLA-AB and Lymphotype HLA-DR-DQ (Bio-Rad Medical 
Diagnostics), LIPA Reverse Dot Blot (Innogenetics Group), or HLA-SSP (Pel Freez, Dynal Biotech LLC). The 
present cohort overlapped significantly with those utilized in our previous publications6,12,21,26. After genotyping 
and imputation, the cohort in the present study included 239 recipient/donor pairs, 23 individual recipients, and 
28 individual donors. The majority (>75%) of GvHD prevention procedures combined cyclosporine, steroid, 
and 3 to 4 doses of methotrexate, while 18% received a combination of cyclosporine and mycophenolate mofetil.
The Spanish cohort was composed of 264 HLA-matched recipient/donor sibling pairs having clinical data and 
DNA samples sent for genotyping. The cohort also included 10 individual recipients and 30 donors without the 
respective sibling. HLA matching was completed at low-resolution at HLA-A and -B loci and at high-resolution 
at the HLA-DRB1 locus. Recipients received allogeneic HSCT between 2002 and 2014 at 13 Spanish transplant 
centers. After genotyping and imputation, the final study cohort was composed of 253 recipient/donor pairs, 15 
individual recipients, and 30 individual donors. For GvHD prevention, 57% of recipients received a combination 
of cyclosporine and methotrexate, 10% received cyclosporine only, and 11% were treated with a combination of 
cyclosporine and mycophenolate mofetil.
The clinical outcomes examined were severe acute and chronic GvHD. The phenotypes compared were 
aGvHD grade 0 versus grades III–IV and absent cGvHD versus extensive cGvHD. Local determinations of GvHD 
grades were used. The samples were graded according to guidelines established by the European Society for Blood 
and Marrow guidelines27,28.
This study conformed to principles of the Declaration of Helsinki and was approved by the Ethics Committee 
of Helsinki University Central Hospital and the DNA bank of the Spanish Group for Stem Cell Transplantation 
(GETH). All participants gave written informed consent.
Genotyping and imputation. Genotyping was performed at FIMM Technology Centre, Helsinki, Finland. 
DNA samples from the Finnish cohort were extracted using the QIAamp DNA Blood Mini Kit (Qiagen) from the 
white blood cell fraction of peripheral blood samples and sent for HLA typing. The Finnish cohort was genotyped 
using an Immunochip (Illumina) array comprising 196524 variants in 2013. DNA samples of the Spanish cohort 
were received from the DNA bank of the GETH. The array utilized for the analysis of Spanish samples from the 
years 2016–17 was the Infinium® ImmunoArray-24 v2.0 (Illumina), which comprises 253702 variants. Initial 
quality control identified samples with discordant sex information, duplicate samples, a call rate <97%, and het-
erozygosity excess <−0.3 (not X chromosome) or >0.2 and >0.1 for the X chromosome.
The autosomal genotype data were imputed with IMPUTE2 using 1000 Genomes Phase 3 as a phased ref-
erence panel29. Pre-filtering of the variants and samples was completed according to the methods described by 
Anderson et al.30. Individuals with a missing genotype >3%, variants with a minor allele frequency (MAF) <1%, 
variants with a missing data rate >5%, and variants with a HWE P-value < 1 × 10−5 were excluded. The princi-
pal components of both cohorts were determined and the imputation procedures were carried out separately. 
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Post-imputation filtering excluded variants having an IMPUTE2 INFO-field measure of the observed statistical 
information <0.531. After post-imputation filtering, 5041081 and 5737173 variants were included in the Finnish 
and Spanish cohort genotype datasets, respectively. The datasets analyzed during the current study are not pub-
licly available due to limitations of ethical permits which do not allow distribution of personal data, including 
individual genetic and clinical results.
Statistical analyses. The significance of variation between characteristics in the study cohorts was analyzed 
using the non-parametric Mann–Whitney U-test (recipient and donor age), Pearson’s chi-square test (transplant 
gender direction, diagnosis, stem cell source, condition regimen, and GvHD grade), or Fisher’s exact test (aplastic 
anemia diagnosis). P-values < 0.05 were considered statistically significant (Table 7).
Principal component analysis (PCA) was used to determine the genetic population structure of the two 
study cohorts. Non-imputed common SNPs shared by the two cohorts were included in the analysis. The SNPs 
were pruned to exclude strong linkage disequilibrium32. The analysis was executed with Plink v1.90b3u (www.
cog-genomics.org/plink/1.9/)33 commands indep-pairwise 50 5 0.8 and pca, and the result was plotted using R 
version 3.3.334. A PCA-plot of the first two dimensions is presented in Supplementary Figure 1.
An association between the SNPs and acute and chronic GvHD was determined using the chi-square allelic 
test and is expressed as the OR with the 95% CI (Tables 1 and 2). The frequencies of the recipients and donors are 
presented in Supplementary Table 5. SNPs with a MAF < 0.01 and HWE 1 × 10−5 were excluded from the anal-
ysis. The current study evaluated results presented before and, therefore, despite multiple tests (77 in the Finnish 
and 97 in the Spanish cohorts), a P-value < 0.05 was considered to support a statistically significant replication. 
Statistical analyses were performed with IBM SPSS Statistics version 24 and PLINK 1.0735.
The eQTL analyses (Tables 3 and 4) were performed in February 2017 utilizing the comprehensive Blood 
eQTL Database (http://genenetwork.nl/bloodeqtlbrowser/) published by Westra et al.16. The database consists 
of both cis- and trans-eQTL results generated from a meta-analysis of seven studies including 5311 peripheral 
blood samples and a replication analysis with 2775 samples. Z-scores with a false detection rate (FDR) <0.05 were 
considered statistically significant.
Characteristic
Finnish 
recipients*
Spanish 
recipients† P
Recipient age, median years (range) 49 (18–65) 50 (8–72) 0.085‡
Donor age, median years (range) 46 (4–65) 47 (3–78) 0.424‡
Recipient-donor gender, n (%)
 Male-male 73 (28) 87 (33) 0.479§
 Male-female 57 (22) 62 (23)
 Female-female 61 (23) 51 (19)
 Female-male 71 (27) 66 (25)
Diagnosis, n (%)
 Acute myeloid leukemia 73 (28) 88 (33) 0.203§
 Acute lymphoblastic leukemia 39 (15) 24 (9) 0.036§
 Chronic myeloid leukemia 37 (14) 13 (5) <0.001§
 Myelodysplastic syndrome 20 (8) 26 (10) 0.390§
 Hodgkin’s lymphoma 0 (0) 12 (5) 0.001§
 Non-Hodgkin’s lymphoma 12 (5) 50 (19) <0.001§
 Myeloma 56 (21) 38 (14) 0.032§
 Aplastic anemia 4 (2) 5 (2) 1.000||
 Other malignancies 21 (8) 11 (4) 0.060§
Stem cell source, n (%)
 Bone marrow 138 (53) 13 (5) <0.001§
 Peripheral blood 124 (47) 254 (95)
Conditioning regimen, n (%)
 Myeloablative 199 (76) 110 (42) <0.001§
 Reduced intensity conditioning 63 (24) 151 (58)
 aGvDH grades III–IV, n (%) 23 (11) 39 (18) 0.044§
 cGvHD, extensive, n (%) 71 (39) 54 (32) 0.156§
Table 7. Characteristics of the Finnish and Spanish recipients. aGvHD indicates acute graft-versus-host disease; 
and cGvHD, chronic graft-versus-host disease. *Finnish recipients underwent allogeneic HSCT at Helsinki 
University Hospital, Comprehensive Cancer Center, Stem Cell Transplantation Unit, Finland, between 1993 
and 2006. †Spanish recipient underwent allogeneic HSCT at 13 Spanish transplant centers between 2002 and 
2014. ‡The significance of variation between characteristics in the study cohorts was analyzed using the non-
parametric Mann–Whitney U-test. §The significance of variation between characteristics in the study cohorts 
was analyzed using the Pearson chi-square test. ||The significance of variation between characteristics in the 
study cohorts was analyzed using the Fisher’s exact test.
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The cytokine QTL database (https://hfgp.bbmri.nl/), recently published by Li Y et al.17, combines the host genet-
ics and cytokine production after various microbial stimuli. The effects of candidate SNPs on the cytokine response 
were analyzed in March 2017 (Tables 5 and 6). P-values < 0.05 were considered to be statistically significant.
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